Microvessel density assessment in canine mammary c... - BV FAPESP
Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Microvessel density assessment in canine mammary carcinomas as a predictive factor for metronomic chemotherapy

Full text
Author(s):
Mendes Ferrari, Analy Ramos [1] ; Ferrari, Heitor Flavio [2] ; Carreira, Vinicius Soares [3] ; Frigerio, Edenilson Dona [4] ; Rui Luvizotto, Maria Cecilia [5] ; de Andrade, Alexandre Lima [5]
Total Authors: 6
Affiliation:
[1] UNESP, FMVA, Programa Posgrad Ciencia Anim, Curso Doutorado, Aracatuba, SP - Brazil
[2] UNIFAI, Ctr Univ Adamantina, Adamantina, SP - Brazil
[3] Vet Path Serv Inc, Mason, OH - USA
[4] UNESP, FMVA, Programa Residencia Med Vet, Aracatuba, SP - Brazil
[5] UNESP, FMVA, Programa Posgrad Ciencia Anim, Aracatuba, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: SEMINA-CIENCIAS AGRARIAS; v. 40, n. 5, p. 1849-1855, SEP-OCT 2019.
Web of Science Citations: 0
Abstract

The canine mammary tumor is the neoplasia that most commonly affects intact female dogs (not spayed) in routine veterinary practice. Canine mammary tumor therapy is a challenge because only few effective treatments have been described for high-grade tumors in veterinary medicine. One such therapeutic option that slows down tumor growth is metronomic chemotherapy (MC), a therapeutic modality that acts by decreasing tumor angiogenesis. Quantification of intratumoral microvessel density (MVD) has been proposed as a means to evaluate the effectiveness of MC in human and canine tumors. In this study, MVD is proposed as a predictive factor for the effectiveness of MC in canine mammary tumors. Twenty female dogs with mammary carcinoma were equally distributed into a mastectomy group treated only with mastectomy, and a MC group treated with MC (cyclophosphamide and piroxicam) orally and daily for 28 days followed by mastectomy. Mammary tumors were classified and graded histologically. MVD was ascertained by CD31 immunostaining. The analysis showed statistically significant difference in MVD scores between groups, corroborating a quantitative reduction in tumor microvasculature in the group treated with MC. Our findings suggest that MVD may be an important predictive factor for the selection of female dogs with malignant mammary tumors that may benefit from MC. (AU)

FAPESP's process: 13/07252-5 - Metronomic chemotherapy in mammary gland carcinomas of bitches and therapy validation
Grantee:Alexandre Lima de Andrade
Support Opportunities: Regular Research Grants